| Title |
Drug design for ever, from hype to hope
|
|---|---|
| Published in |
Perspectives in Drug Discovery and Design, January 2012
|
| DOI | 10.1007/s10822-011-9519-9 |
| Pubmed ID | |
| Authors |
G. Seddon, V. Lounnas, R. McGuire, T. van den Bergh, R. P. Bywater, L. Oliveira, G. Vriend |
| Abstract |
In its first 25 years JCAMD has been disseminating a large number of techniques aimed at finding better medicines faster. These include genetic algorithms, COMFA, QSAR, structure based techniques, homology modelling, high throughput screening, combichem, and dozens more that were a hype in their time and that now are just a useful addition to the drug-designers toolbox. Despite massive efforts throughout academic and industrial drug design research departments, the number of FDA-approved new molecular entities per year stagnates, and the pharmaceutical industry is reorganising accordingly. The recent spate of industrial consolidations and the concomitant move towards outsourcing of research activities requires better integration of all activities along the chain from bench to bedside. The next 25 years will undoubtedly show a series of translational science activities that are aimed at a better communication between all parties involved, from quantum chemistry to bedside and from academia to industry. This will above all include understanding the underlying biological problem and optimal use of all available data. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 176 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 2% |
| Germany | 3 | 2% |
| Brazil | 2 | 1% |
| Colombia | 1 | <1% |
| Portugal | 1 | <1% |
| Italy | 1 | <1% |
| Bulgaria | 1 | <1% |
| Malaysia | 1 | <1% |
| Czechia | 1 | <1% |
| Other | 3 | 2% |
| Unknown | 158 | 90% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 38 | 22% |
| Student > Ph. D. Student | 36 | 20% |
| Student > Master | 23 | 13% |
| Student > Bachelor | 14 | 8% |
| Professor | 10 | 6% |
| Other | 32 | 18% |
| Unknown | 23 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 49 | 28% |
| Chemistry | 43 | 24% |
| Biochemistry, Genetics and Molecular Biology | 14 | 8% |
| Computer Science | 10 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 5% |
| Other | 25 | 14% |
| Unknown | 26 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 October 2018.
All research outputs
#3,430,408
of 25,457,858 outputs
Outputs from Perspectives in Drug Discovery and Design
#117
of 949 outputs
Outputs of similar age
#26,291
of 251,889 outputs
Outputs of similar age from Perspectives in Drug Discovery and Design
#5
of 22 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 949 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 251,889 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.